Creative Medical Technology (CELZ) Competitors $2.16 -0.08 (-3.35%) As of 10:01 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CELZ vs. ME, SNTI, CMMB, GLYC, ELEV, CARM, NXTC, MEIP, COCP, and SLGLShould you be buying Creative Medical Technology stock or one of its competitors? The main competitors of Creative Medical Technology include 23andMe (ME), Senti Biosciences (SNTI), Chemomab Therapeutics (CMMB), GlycoMimetics (GLYC), Elevation Oncology (ELEV), Carisma Therapeutics (CARM), NextCure (NXTC), MEI Pharma (MEIP), Cocrystal Pharma (COCP), and Sol-Gel Technologies (SLGL). These companies are all part of the "pharmaceutical products" industry. Creative Medical Technology vs. 23andMe Senti Biosciences Chemomab Therapeutics GlycoMimetics Elevation Oncology Carisma Therapeutics NextCure MEI Pharma Cocrystal Pharma Sol-Gel Technologies 23andMe (NASDAQ:ME) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability, community ranking and analyst recommendations. Which has more risk and volatility, ME or CELZ? 23andMe has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, Creative Medical Technology has a beta of 2.01, meaning that its stock price is 101% more volatile than the S&P 500. Is ME or CELZ more profitable? Creative Medical Technology has a net margin of 0.00% compared to 23andMe's net margin of -183.39%. Creative Medical Technology's return on equity of -63.05% beat 23andMe's return on equity.Company Net Margins Return on Equity Return on Assets 23andMe-183.39% -170.07% -62.13% Creative Medical Technology N/A -63.05%-60.42% Does the MarketBeat Community favor ME or CELZ? Creative Medical Technology received 59 more outperform votes than 23andMe when rated by MarketBeat users. Likewise, 68.93% of users gave Creative Medical Technology an outperform vote while only 46.15% of users gave 23andMe an outperform vote. CompanyUnderperformOutperform23andMeOutperform Votes1246.15% Underperform Votes1453.85% Creative Medical TechnologyOutperform Votes7168.93% Underperform Votes3231.07% Does the media refer more to ME or CELZ? In the previous week, 23andMe had 21 more articles in the media than Creative Medical Technology. MarketBeat recorded 22 mentions for 23andMe and 1 mentions for Creative Medical Technology. Creative Medical Technology's average media sentiment score of 0.77 beat 23andMe's score of -0.02 indicating that Creative Medical Technology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 23andMe 1 Very Positive mention(s) 3 Positive mention(s) 13 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Neutral Creative Medical Technology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings and valuation, ME or CELZ? Creative Medical Technology has lower revenue, but higher earnings than 23andMe. Creative Medical Technology is trading at a lower price-to-earnings ratio than 23andMe, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio23andMe$208.78M0.06-$666.70M-$15.45-0.03Creative Medical Technology$11K355.96-$5.29M-$3.71-0.60 Do insiders and institutionals hold more shares of ME or CELZ? 36.1% of 23andMe shares are owned by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are owned by institutional investors. 26.3% of 23andMe shares are owned by insiders. Comparatively, 2.8% of Creative Medical Technology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts rate ME or CELZ? 23andMe currently has a consensus target price of $9.40, indicating a potential upside of 1,787.55%. Given 23andMe's stronger consensus rating and higher probable upside, analysts clearly believe 23andMe is more favorable than Creative Medical Technology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 23andMe 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Creative Medical Technology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryCreative Medical Technology beats 23andMe on 10 of the 17 factors compared between the two stocks. Remove Ads Get Creative Medical Technology News Delivered to You Automatically Sign up to receive the latest news and ratings for CELZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CELZ vs. The Competition Export to ExcelMetricCreative Medical TechnologyBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.92M$2.98B$5.54B$7.50BDividend YieldN/A1.53%4.86%4.04%P/E Ratio-0.5930.4323.2418.07Price / Sales355.96383.25361.2586.83Price / CashN/A168.6838.1634.64Price / Book0.303.646.493.99Net Income-$5.29M-$72.06M$3.21B$247.18M7 Day Performance-1.32%-9.02%-4.91%-4.25%1 Month Performance-62.60%-16.50%-0.08%-6.87%1 Year Performance-59.49%-31.37%6.40%-3.73% Creative Medical Technology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CELZCreative Medical Technology1.6152 of 5 stars$2.17-3.3%N/A-59.3%$3.78M$11,000.00-0.575ME23andMe1.3137 of 5 stars$0.63-13.2%$9.40+1,382.6%-95.2%$17.01M$208.78M-0.04770Gap DownHigh Trading VolumeSNTISenti Biosciences2.8491 of 5 stars$3.51-5.6%$10.00+184.9%-12.0%$16.95M$2.56M-0.234Gap UpCMMBChemomab Therapeutics3.2086 of 5 stars$1.18-5.2%$9.00+666.0%+32.6%$16.87MN/A-1.1820GLYCGlycoMimetics1.2617 of 5 stars$0.26-1.0%$8.00+2,965.1%-93.3%$16.84M$10,000.000.0050News CoverageELEVElevation Oncology2.074 of 5 stars$0.28-2.1%$3.39+1,092.2%-95.0%$16.82MN/A-0.3540Gap DownCARMCarisma Therapeutics2.8971 of 5 stars$0.39-2.0%$4.94+1,179.8%-90.2%$16.58M$20.27M-0.2520Upcoming EarningsAnalyst ForecastNews CoverageGap DownNXTCNextCure4.0222 of 5 stars$0.57-5.7%$3.50+509.8%-83.5%$16.08MN/A-0.2790News CoverageGap DownMEIPMEI Pharma3.7868 of 5 stars$2.35flat$7.00+197.9%-47.4%$15.66M$65.30M-0.41100Gap DownCOCPCocrystal Pharma3.1313 of 5 stars$1.53-3.2%$7.00+357.5%-2.8%$15.57MN/A-0.8310Analyst RevisionNews CoveragePositive NewsGap DownSLGLSol-Gel Technologies2.6159 of 5 stars$0.56-2.3%$5.00+797.7%-52.4%$15.52M$11.71M-1.6450Positive NewsGap Down Remove Ads Related Companies and Tools Related Companies 23andMe Alternatives Senti Biosciences Alternatives Chemomab Therapeutics Alternatives GlycoMimetics Alternatives Elevation Oncology Alternatives Carisma Therapeutics Alternatives NextCure Alternatives MEI Pharma Alternatives Cocrystal Pharma Alternatives Sol-Gel Technologies Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CELZ) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Creative Medical Technology Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Creative Medical Technology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
